logo-loader
Genedrive PLC

Genedrive - Capital Network: Ready to launch the first point-of-care HepC test

genedrive (GDR.LON), an emerging UK medtech company, focuses on the development and commercialization of an innovative, point-of-care diagnostic system, also called Genedrive® (in this report, "genedrive" (GDR.LON) refers to the company, whereas "Genedrive®" indicates the product). genedrive (GDR.LON) is poised to become the first company to launch a decentralized Hepatitis C diagnostic, entering a large market at a time when new curative therapies for the disease are transforming opportunities for testing and treatment. A Genedrive® TB diagnostic has already been launched and the platform has a wide range of alternative applications.

Executive summary

In the coming months we expect genedrive to update the market on several key fronts:    

• CE mark for the HepC Genedrive® system expected by mid-2017

• Distribution agreements for the commercialization of the HepC device in high burden countries

• Launch of Genedrive® for the diagnosis of HepC

• Next steps for Genedrive® development in other diseases

• Ongoing strategic reassessment of their legacy CRO business

Quick facts: Genedrive PLC

Price: £0.18

Market: AIM
Market Cap: £6.15 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genedrive PLC named herein, including the promotion by the Company of Genedrive PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Genedrive PLC optimistic on the long-term opportunity for its HCV test

Genedrive PLC (LON:GDR) CEO David Budd tells Proactive London's Andrew Scott he remains confident the World Health Organisation will pre-qualify its HCV ID hepatitis C test in the near term despite some delays to the clinical trial. He adds that the development of an antibiotic-induced...

on 12/7/19

5 min read